CJC-1295 (no DAC)
5 mg · Lyophilized powder
Sold out
29-amino-acid GHRH (1-29) analogue without DAC.
Need larger quantities? Wholesale pricing for qualified businesses
For laboratory research use only by qualified researchers. Not for human or veterinary use. Not a drug, dietary supplement, cosmetic or food. Not evaluated by the FDA for any use.
Quick Summary
Not approved — little direct researchCJC-1295 without DAC, also called modified GRF (1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions. It lacks the albumin-binding linker of CJC-1295 with DAC, the form tested in published human studies. Very little research has examined the no-DAC peptide on its own, and it is not approved.
Areas of research
- Growth hormone regulation
- Long-acting GHRH analogues
- Anti-doping science
- Forensic analysis
- Amount
- 5 mg
- Form
- Lyophilized powder
- References
- 5 cited
- COA
- Batch report pending
- Free U.S. shipping on orders of $150 or more
- Lyophilized powder in a sealed vial
Research Use Notice. This product is intended for laboratory and research purposes. It is not intended for human consumption or personal medical use. Product information is provided for scientific and educational context only. See our Research Use Policy.
Why Researchers Study It
- How a modified GHRH(1-29) peptide behaves without albumin binding, compared with the long-acting DAC version
- GHRH receptor signaling and growth hormone release from the pituitary
- Growth hormone pulse patterns during sustained GHRH-receptor stimulation (studied with the DAC version)
- Identification of GHRH analogues by anti-doping laboratories
What It Is
Growth hormone-releasing hormone (GHRH) is the brain signal that tells the pituitary gland to release growth hormone.
Growth hormone-releasing hormone (GHRH) is the brain signal that tells the pituitary gland to release growth hormone. Its first 29 amino acids, GHRH(1-29), are the starting point for several synthetic analogues.
CJC-1295 without DAC is a GHRH(1-29) amide with four amino acid substitutions. It is also sold as modified GRF (1-29) or mod GRF 1-29.
The name CJC-1295 was first used for a related drug that adds a lysine linker carrying a maleimide group to this peptide. In the body, that group binds covalently to serum albumin; in healthy adults the half-life was estimated at about 6 to 8 days. This albumin-binding version is what "with DAC" refers to.
The no-DAC peptide does not carry that linker, so results for the albumin-bound drug, including its long action, should not be assumed for it. In 2010 a Norwegian anti-doping laboratory identified a 29-amino-acid amidated peptide matching CJC-1295 in an unknown preparation seized by police and customs.
How It Works
2 established · 2 proposed or under investigation
Established
- As a GHRH(1-29) analogue, it is designed to act on the GHRH receptor of the anterior pituitary, which triggers growth hormone release
- CJC-1295 with DAC binds covalently to serum albumin through a maleimide linker; the no-DAC peptide lacks this linker
Proposed / under investigation
- A much shorter duration of action than the DAC version, because it cannot bind albumin (expected from its structure; not well measured in published studies)
- In healthy men given the DAC version, growth hormone pulses persisted while baseline levels rose; whether the no-DAC peptide produces similar patterns is untested
Research Status & Evidence
Not approved — little direct research
Published human studies tested CJC-1295 with DAC, a different, albumin-binding molecule. No clinical study of the no-DAC peptide was identified.
Types of evidence
- Not available: Cell & lab studies
- Not available: Animal studies
- Available: Early human studies
- Not available: Clinical trials
- Not available: Approved medical use
Direct published data on the no-DAC peptide are scarce. The human studies usually cited, small 2006 studies in healthy adults, tested CJC-1295 with DAC, a different molecule whose long action depends on albumin binding. Their results should not be attributed to the no-DAC form without new data.
Areas of research
- Growth hormone regulationGHRH receptor pharmacology
- Long-acting GHRH analogueshuman studies of the DAC version
- Anti-doping scienceCJC-1295 named by WADA as a GHRH analogue
- Forensic analysisidentification in seized products
Limitations
- No CJC-1295 product, with or without DAC, is FDA-approved
- Published human data describe the DAC version, not this peptide
- FDA's compounding safety-risk page lists CJC-1295 (form not specified) among withdrawn Category 2 nominations, citing serious adverse events including increased heart rate and a systemic vasodilatory reaction, and limited clinical data
- CJC-1295 is named among GHRH analogues prohibited at all times under the WADA 2026 Prohibited List
Specifications
5 mg · Lyophilized powder
- Product
- CJC-1295 (no DAC)
- Category
- Peptides
- Size
- 5 mg
- Form
- Lyophilized powder
- Synonyms
- Modified GRF (1-29); Mod GRF 1-29; CJC-1295 without DAC; Tetrasubstituted GRF (1-29)
- SKU
- REN-CJC-5
Testing & COA Batch report pending
Research References (5)
Linked sources · last reviewed October 2026
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006 · PubMed 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006 · PubMed 17018654
- Henninge J et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal 2010 · PubMed 21204297
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (updated April 2026) · fda.gov
- WADA. The 2026 Prohibited List, section S2.2.4 (copy published by JADCO) · jadco.gov.jm
Summaries are written by Renuvia Labs from the sources above for educational context only. Last reviewed October 30, 2026.
Frequently Asked Questions
Is CJC-1295 no DAC the same as mod GRF 1-29?
Yes. CJC-1295 without DAC, modified GRF (1-29) and mod GRF 1-29 are names for the same peptide: a GHRH(1-29) amide with four amino acid substitutions.
What is the difference between CJC-1295 with and without DAC?
The name CJC-1295 was first used for a drug that adds a lysine linker carrying a maleimide group (the Drug Affinity Complex, or DAC) to this peptide, so that it binds to serum albumin. This listing is the peptide without that linker. The published human CJC-1295 studies tested the DAC version.
When will CJC-1295 (no DAC) be available?
CJC-1295 (no DAC) is sold out right now. Use "Email me when it's available" on this page and we send one email when it is back in stock. Every lot is listed in the COA library with its Certificate of Analysis once the lab issues it.
What size is the CJC-1295 (no DAC) vial?
CJC-1295 (no DAC) is supplied as a single 5 mg lyophilized vial (5 mg total peptide content stated on the label).
What is CJC-1295 (no DAC)?
CJC-1295 without DAC, also called modified GRF (1-29), is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions. It lacks the albumin-binding linker of CJC-1295 with DAC, the form tested in published human studies. Very little research has examined the no-DAC peptide on its own, and it is not approved.
Is there a CJC-1295 (no DAC) coupon or discount code?
There is no public coupon code. New customers get a first-order discount for joining the Renuvia email list, volume pricing starts at 2 vials of CJC-1295 (no DAC), and U.S. shipping is free over $150. Codes on third-party coupon sites are not valid here.
What are other names for CJC-1295 (no DAC)?
CJC-1295 (no DAC) is also referred to as Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC, Tetrasubstituted GRF (1-29).
What sizes is Renuvia Labs CJC-1295 (no DAC) available in?
CJC-1295 (no DAC) is listed in 5 mg, supplied as lyophilized powder in a sealed glass vial. It is sold for laboratory research use only.
Where is the Certificate of Analysis for CJC-1295 (no DAC)?
Certificates of Analysis are published per lot in the Renuvia Labs COA library, searchable by product, SKU or lot number. CJC-1295 (no DAC) shows "pending" there until the current lot's report exists; it is then linked on this page too.
Is this in stock?
Yes, unless the page says sold out. You reserve it with no payment today, and we email payment instructions in approximately 1–2 business days. Your order ships once payment arrives.
What form is this product supplied in?
Peptides and research compounds ship as lyophilized (freeze-dried) powder in a sealed glass vial. The fill amount printed on the product page and label is the total content of the vial.
Is this product for human use?
No. All Renuvia Labs products are sold strictly for laboratory research use. They are not for human or animal consumption and are not intended to diagnose, treat, cure or prevent any disease.
Do you offer volume pricing?
Yes. Per-vial pricing drops automatically at 2, 3 and 5 vials of the same product; the current tiers are shown next to the price. For larger quantities, see our wholesale program.
How much is shipping?
Free U.S. shipping on orders of $150 or more; $8.95 flat rate below that.
Do you ship outside the U.S.?
No. Renuvia Labs ships to U.S. addresses only. Research institutions outside the U.S. can enquire through the wholesale program.
